Literature DB >> 2723452

HTLV-1 infection in Papua New Guinea: evidence for serologic false positivity.

J N Weber1, N Banatvala, S Clayden, K P McAdam, S Palmer, H Moulsdale, J Tosswill, P Dilger, R Thorpe, S Amann.   

Abstract

Serum samples from 557 individuals participating in studies from four separate lowland and highland populations in Papua New Guinea exhibited consistently false-positive results for human T lymphotropic virus (HTLV) type 1 (10%) and human immunodeficiency virus (HIV) type 1 (5%) antibody in direct antiglobulin and agglutination assays. All serum samples were negative in competitive ELISAs and radioimmunoassays for HTLV-1 and HIV-1; selected samples of reactive sera were negative in an HTLV-2 competitive ELISA. Immunofluorescent antibody tests using HTLV-1 infected cells correlated poorly with ELISA results. None of the sera from Papua New Guinea neutralized vesicular stomatitis virus pseudotypes of HTLV-1. By Western blot analysis, only three serum samples were weakly reactive to HTLV-1 gag proteins. These studies suggest there is as yet no firm evidence of HTLV-1, HTLV-2, or HIV-1 infection in Papua New Guinea, although there may be a low prevalence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723452     DOI: 10.1093/infdis/159.6.1025

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  HTLV-I antibody studies in villagers in East Sepik Province, Papua New Guinea.

Authors:  R C Sanders; A Levin; G Anian; I Webber; H Lee; P Swanson; A Diwan; R Desowitz; W A Blattner; M P Alpers
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 2.  HTLV-I infection in Britain.

Authors:  J Weber
Journal:  BMJ       Date:  1990-07-14

Review 3.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

4.  A serosurvey for HTLV-I among high-risk populations and normal adults in Egypt.

Authors:  N T Constantine; M Fathi Sheba; A L Corwin; R S Danahy; J D Callahan; D M Watts
Journal:  Epidemiol Infect       Date:  1991-10       Impact factor: 2.451

5.  Use of dried blood spots for the detection and confirmation of HTLV-I specific antibodies for epidemiological purposes.

Authors:  S P Parker; M B Taylor; A E Ades; W D Cubitt; C Peckham
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

6.  Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua New Guinea.

Authors:  M P Sherman; N K Saksena; D K Dube; R Yanagihara; B J Poiesz
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Highly divergent molecular variants of human T-lymphotropic virus type I from isolated populations in Papua New Guinea and the Solomon Islands.

Authors:  A Gessian; R Yanagihara; G Franchini; R M Garruto; C L Jenkins; A B Ajdukiewicz; R C Gallo; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

8.  Isolation of a human T-lymphotropic virus type I strain from Australian aboriginals.

Authors:  I Bastian; J Gardner; D Webb; I Gardner
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Antenatal survey for the seroprevalence of HTLV-1 infections in the West Midlands, England.

Authors:  S Nightingale; D Orton; D Ratcliffe; S Skidmore; J Tosswill; U Desselberger
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

10.  Characterization of a variant of human T-lymphotropic virus type I isolated from a healthy member of a remote, recently contacted group in Papua New Guinea.

Authors:  R Yanagihara; V R Nerurkar; R M Garruto; M A Miller; M E Leon-Monzon; C L Jenkins; R C Sanders; P P Liberski; M P Alpers; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.